ARGUS Retained by Nextant Aerospace for Research Initiative

Posted on by

CINCINNATI , Oct. 17, 2013 /CNW/ - ARGUS International, Inc's Market Intelligence division has been retained by Nextant Aerospace to conduct research designed to validate their next product launch. After extensive internal analysis of their future aircraft platforms, Nextant specifically tasked ARGUS with reviewing the viability of the entry level market place.

"We are very pleased Nextant Aerospace selected ARGUS Market Intelligence to conduct this research," said Shirley Mason , ARGUS International Senior Vice President. "ARGUS believes that Nextant has chosen a growth segment that will continue to thrive for the foreseeable future." She continued: "There are many advantages of an entry level aircraft as a solution for an experienced corporate operator or a new arrival to business aircraft use. This aircraft segment can access the maximum number of airports available and they command operating costs commensurate with their smaller size." This segment is positioned for growth in both the domestic and international markets and Nextant's successful track record in this space makes them uniquely qualified to further expand this category.

About Nextant Aerospace

Nextant Aerospace is recognized as the first company in the world to introduce aircraft remanufacturing to the business jet market. The Nextant 400XTi is a completely rebuilt Beechjet 400A/XP with Williams FJ44-3AP engines and the Rockwell Collins Pro Line 21 integrated avionics suite. The new aircraft also has major aerodynamic enhancements and an improved engine mounting configuration with redesigned nacelles and pylons. The 400XTi is delivered with a two-year full-aircraft warranty and after-sales support provided by a global network of owned and authorized service centers. Founded in 2007, Nextant is based in Cleveland, Ohio . Nextant is a Directional Aviation Capital company. For more information, please visit http://www.nextantaerospace.com, like us on Facebook, follow us on Twitter @nextantaero or join us on LinkedIn.

About Market Intelligence

Market Intelligence, a division of ARGUS International, Inc. (ARGUS), provides valuable information to the aviation community for the purpose of accurate and confident decision making in determining market opportunity, market activity, market penetration strategy, and market development metrics. Products include TRAQPak Pro aircraft activity Market Intelligence program, TRAQPak FBO, Travel Assessments, CompAir, Aircraft Operating Cost reports, advisory services, and market research.

ARGUS is a specialized aviation services company with global expertise whose mission is to provide the aviation marketplace with the information needed to make informed decisions and manage risk. Founded in 1995, ARGUS is headquartered in Cincinnati, OH , and actively engaged with business activities in North America , Europe , Australia , Asia , South America and the Middle East and Africa .

SOURCE ARGUS International, Inc.

See the original post here:

ARGUS Retained by Nextant Aerospace for Research Initiative

Experimental Physiology meeting report: Neuroendocrine regulation of the mammalian reproductive axis – Video

Posted on by


Experimental Physiology meeting report: Neuroendocrine regulation of the mammalian reproductive axis
William Colledge reports on the meeting from April 2013 in Boston USA. Read full reports at: http://ep.physoc.org/content/98/11.toc Neuroendocrine regulation of the mammalian reproductive axis.

By: PhysocTV

See the rest here:
Experimental Physiology meeting report: Neuroendocrine regulation of the mammalian reproductive axis - Video

Canadian scientists fine-tune possible Ebola virus therapy

Posted on by

TORONTO - Scientists at Canada's National Microbiology Laboratory are continuing to fine-tune a possible treatment for Ebola virus infection, one of the deadliest known to humankind.

In a newly published article, the Winnipeg-based scientists reported that their combination therapy saved three of four cynomolgus macaques and four of four rhesus macaques when it was given three days after the animals were infected with Ebola Zaire, the deadliest strain.

The scientists hope to test the drug cocktail in humans beginning in late 2014 or early 2015, if they can get approval from Canadian and U.S. drug regulators.

The work builds on earlier research which showed a cocktail of three cloned antibodies saved four of four primates when given 24 hours after infection and two of four treated 48 hours after infection.

This time the researchers added interferon-alpha, a chemical made by the immune system, to the treatment regime.

Two of four primates survived when they were given the chemical one day after infection, and then the antibody cocktail four days later.

In order for a treatment to be useful against the five types of Ebola viruses or their cousin, the Marburg virus, it must be something that can enhance survival when given days after infection, which is when cases would typically come to light.

"The concept of combining different treatments to improve efficacy and extend the treatment window is certainly interesting and the data look promising," Tom Geisbert, an expert in viral hemorrhagic fevers, said of the work. Geisbert is a researcher at the University of Texas Medical Branch in Galveston.

The senior author of the study is Gary Kobinger, head of the special pathogens program at the Winnipeg lab. The laboratory is part of the Public Health Agency of Canada.

He said in an interview that the aim of this work is to find a way to put a lid on the infection, to give the immune system a chance to fight it off.

Read the original here:
Canadian scientists fine-tune possible Ebola virus therapy

Research and Markets: Global Clinical Laboratory Services Market to 2019: Clinical Chemistry, Medical Microbiology …

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/5w7f6f/clinical) has announced the addition of the "Clinical Laboratory Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

The global market for clinical laboratory services is expected to record a CAGR of 5.8% during the forecast period of 2013 to 2019, to grow from a USD 162.71 billion market in 2012 to a USD 241.37 billion market in 2019

The clinical diagnostic tests performed by laboratories can be broadly classified into four major categories, namely, clinical chemistry, medical microbiology & cytology, human and tumour genetics and other esoteric tests. Ranging from routine blood and urine tests to high-end genetic analysis including fluorescence in situ hybridization (FISH), molecular expression testing etc., clinical laboratories offer numerous tests that help detect disease progression and abnormalities. The three major types of service providers in this market include hospital-based laboratories, clinic-based laboratories and stand-alone laboratories.

With the increasing incidence rates of debilitating conditions such as cancer, diabetes and infectious diseases, the number of patients that will opt for such tests will continue to increase in the future and thereby increase the demand for these services. Moreover, the percentage of aged population in the U.S. is expected to grow to an estimated 20% by 2030. Such a large population of elderly people in the U.S. alone will lead to high testing volumes for clinical laboratories. Diagnostics manufacturers such as Roche Holdings, Genomic Health, Abbott Diagnostics, Qiagen, etc. are focusing their efforts towards developing products and systems that would enable highly accurate analysis of patient samples and also enable processing of thousands of samples at a time. This will help clinical laboratories to cope with the rising demand and in turn ensure revenue generation.

The market is highly oligopolistic in nature with a few major players accounting for more than 50% of the market. Some of the market leaders in this space include Laboratory Corporation of America Holdings, Quest Diagnostics, Inc., Sonic Healthcare, Healthscope, Genoptix Medical Laboratory, Labco S.A., Charles River Laboratories, Bio-Reference Laboratories, Spectra Laboratories, and Abbott Laboratories.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Market Overview

Read the original:
Research and Markets: Global Clinical Laboratory Services Market to 2019: Clinical Chemistry, Medical Microbiology ...

Men-only hepatitis B mutation explains higher cancer rates

Posted on by

PUBLIC RELEASE DATE:

17-Oct-2013

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer. Although some women do progress to cirrhosis and liver cancer, the mutation is absent in HBV in women. The research is published ahead of print in the Journal of Clinical Microbiology.

"This is the first mutation found that can explain the gender disparity in incidence of hepatocellular carcinoma," says Bum-Joon Kim of Seoul National University, Korea, an author on the study.

In the study, the researchers randomly collected and analyzed serum samples from 292 patients with chronic HBV infection who visited one of 3 hospitals in Korea from 2003-2005. Previous studies had suggested that a gene mutation known as W4P/R was associated with higher incidence of liver cancer and cirrhosis. They developed an assay to specifically identify HBV with the W4P/R mutation. When compared to patient outcomes, the W4P/R mutation was significantly associated with severe liver disease and was found exclusively in male patients.

The investigators believe the assay they developed to discover the mutation may hold promise as a diagnostic for predicting male progression to cirrhosis and liver cancer. They caution that first larger studies are necessary to confirm their findings, as only 67 of the 292 samples came from women.

HBV infection is a global health problem, with 350 million chronic carriers of the virus, a number that is roughly equivalent to the combined populations of the US and Canada. The prevalence of infection ranges from less than half a percent in the United States to around 10 percent in Asia, to as high as 15 percent in parts of Africa. Major means of transmission include injection drug abuse, unprotected sex, and transmission via childbirth. Worldwide mortality is about 600,000 annually, according to the World Health Organization. In the US, despite the availability of a vaccine, an estimated 3,000 die annually from hepatocellular cancer or chronic liver disease caused by hepatitis B.

###

A copy of the manuscript can be found online at http://bit.ly/asmtip1013a. Formal publication is scheduled for the December 2013 issue of Journal of Clinical Microbiology.

Read this article:
Men-only hepatitis B mutation explains higher cancer rates

The American Academy of Anti-Aging Medicine (A4M) to Host Medical Education Event at the Westin Diplomat Hotel in …

Posted on by

Boca Raton, FL (PRWEB) October 17, 2013

Inflammation is a major and underestimated cause of many serious and chronic health conditions. Inflammation can cause or worsen cancer, heart disease, and Lyme disease, among others.

Some objectives of the Inflammation Symposium include outlining new areas of research, learning the connections between the GI and nervous systems, and assessing immunological differences between innate and specific immunity.

Speakers featured in this symposium include David Brady, MD; Andrew Heyman, MD, MHSA; Jim LaValle, RPh, CCN, ND; Todd LePine, MD; and Mark Rosenberg, MD.

The Fellowship in Anti-Aging and Regenerative Medicine (FAARM) Module I(D)-Advanced Endocrinology will focus on sexuality, lower urinary tract symptoms, prostate cancer, and the use of hormonal therapies in the male patient.

Speakers include Michael Belfiore, DO; Pamela Smith, MD, MPH, MS; Jack Monaco, MD; Lena Edwards, MD; Gary Huber, DO; Benoit Tano, MD, PhD; Edward Linkner, MD; and Sahar Swidan, Pharm.D, BCPS.

For more information or to register for this CME event, please visit http://www.a4m.com or call 1.888.997.0112.

#####

About the American Academy of Anti-Aging Medicine

As a federally registered 501(c)3 non-profit organization, the American Academy of Anti-Aging Medicine (A4M) is the world's largest non-profit scientific society of physicians and scientists dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process.

Go here to see the original:
The American Academy of Anti-Aging Medicine (A4M) to Host Medical Education Event at the Westin Diplomat Hotel in ...

Davao to join world travel market in UK

Posted on by

DAVAO City's participation as part of the Philippine delegation to the 2013 World Travel Market (WTM) slated at Excel London in the United Kingdom from November 4 to 7 has already been approved by Mayor Rodrigo Duterte, a city official said.

Davao City Tourism Operations Office officer-in-charge Lisette Marques told reporters Wednesday that they are currently processing the necessary documents and their visas.

She will be travelling with Councilor Al Ryan Alejandre, committee chair on tourism and beautification; a tour operator; a resort representative; and a tourism officer of Davao del Sur.

Marques said that Davao is the only region in Mindanao to have been selected by the Department of Tourism's (DOT) Tourism Promotions Board to exhibit in the 300 square meter Philippine Pavillion. Davao City will also be the only local government unit to represent the region.

Marques said the city's participation in the London exhibit will be a big opportunity to present Davao and the Philippines to the world since the event's format will be business to business. She explained that with this format they will be able to reach to a much more wider market especially to the tour operators.

They have also prepared digital copies of their promotion materials for the operators to use and also for the DOT offices in London.

"We are happy that the tourism promotions board have chosen Davao City to be a travel hub for Mindanao for now. And in the coming years, when we have made our mark internationally, we can then move on to Davao and beyond," said Marques.

She added that they will also be promoting the Philippines as a whole and making foreigners see that there are more things to see beyond Manila.

Almasor (Albay, Masbate, and Sorsogon), Cordillera, and private stakeholders like airlines, hotels, and resorts will also be exhibiting in the pavillion.

Leading global travel event for the travel industry WTM had a total of 47,425 participants and 28,780 visitors from 184 countries.

More:

Davao to join world travel market in UK

do you need super computer to max out the latest games in 720p (gtx 660 test) – Video

Posted on by


do you need super computer to max out the latest games in 720p (gtx 660 test)
do you need super computer to max out the latest games in 720p find out in this video . i test far cry 3 ,battlefield 3 ,hitman absolution, batman arkham cit...

By: ALI GBAREEN

Original post:

do you need super computer to max out the latest games in 720p (gtx 660 test) - Video

Purtier Placenta Live Stem Cell Therapy Miracle – Mr Lee Kay Hoy – Osteoporosis, Sensitive Nose – Video

Posted on by


Purtier Placenta Live Stem Cell Therapy Miracle - Mr Lee Kay Hoy - Osteoporosis, Sensitive Nose
Purtier Placenta Live Stem Cell Therapy Miracle - Mr Lee Kay Hoy - Osteoporosis, Sensitive Nose For more information please email us with your contact number...

By: Purtier Placenta Singapore Original

Originally posted here:

Purtier Placenta Live Stem Cell Therapy Miracle - Mr Lee Kay Hoy - Osteoporosis, Sensitive Nose - Video